Healthcare ❯ Regulatory Affairs

FDA Approvals

Drug Development Medical Device Clearance Drug Applications Drug Indications Drug Safety Drug Pricing Drug Approval Process Drug Approvals Medical Devices Clinical Trials New Drug Formulations Drug Launches Brinsupri Metabolic Disorders Drug Submissions Veterinary Medicine Drug Efficacy Drug Competition Drug Testing Drug Trials Breakthrough Therapy Designation Diagnostic Tests Compounding Pharmacy Medical Technology

FDA Clears Libre Duo 10 Day as First Wearable to Track Ketones and Glucose

The authorization could give patients earlier warning of rising ketones to help prevent diabetic ketoacidosis.

Hims & Hers Beats Revenue Estimates but Swings to Quarterly Loss

Natera Shares Surge After Blowout Signatera Quarter and Japan Approval

Dexcom Beats Q2 Expectations and Lifts 2026 Outlook

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

Evolus Posts Q1 Growth and Second Straight Positive Adjusted EBITDA, Reaffirms 2026 Outlook

ARCHIMED to Acquire Esperion for $3.16 a Share Plus CVR

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Boston Scientific Slumps to 52-Week Low After Watchman Trial Jitters and Downgrade

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Repurposed Epilepsy Drug Cuts Sleep Apnea Events by Up to 47% in Phase II Trial

Ironwood Sees LINZESS Above $1.1 Billion in 2026 as FDA-Aligned STARS II Nears Launch

Dexcom Posts Q4 Beat, Launches 15‑Day G7, Reaffirms 2026 Outlook

BioMarin to Acquire Amicus for $4.8 Billion in Cash

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Regeneron Tops Q3 Forecasts on Dupixent Strength as Eylea HD Faces FDA Delay

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial